Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $153 | $278 | $274 | $131 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $1 | $0 | $1 |
| Inventory | $0 | $0 | $0 | -$1 |
| Other Curr. Assets | $7 | $17 | $6 | $8 |
| Total Curr. Assets | $160 | $295 | $280 | $139 |
| Property Plant & Equip (Net) | $14 | $9 | $7 | $9 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $7 | $3 | $3 | $2 |
| Total NC Assets | $20 | $13 | $10 | $11 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $181 | $308 | $291 | $150 |
| Liabilities | – | – | – | – |
| Payables | $9 | $11 | $8 | $9 |
| Short-Term Debt | $2 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $2 |
| Other Curr. Liab. | $30 | $43 | $17 | $10 |
| Total Curr. Liab. | $41 | $56 | $28 | $22 |
| LT Debt | $6 | $208 | $205 | $70 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $5 |
| Total NC Liab. | $6 | $208 | $205 | $76 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $3 | $3 | $0 |
| Total Liabilities | $47 | $264 | $233 | $98 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $150 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$106 | -$614 | -$372 | -$227 |
| AOCI | $0 | $0 | $0 | -$150 |
| Other Equity | $240 | $657 | $430 | $280 |
| Total Equity | $134 | $44 | $58 | $52 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $181 | $308 | $291 | $150 |
| Net Debt | -$145 | -$68 | -$67 | -$59 |